SGMT Company Profile and Key Details

Sagimet Biosciences Inc. (NASDAQ:SGMT) closed at $10.86 USD, gaining $0.15 (1.40%) from the previous close of $10.71. The stock is currently within 5% of its 52-week high $4.50 and $11.27. With a market capitalization of about $353.84 million, Sagimet Biosciences Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.49). Key stats such as the average daily volume over the past year has been around 1.26 million shares, in line with its 52-week average. Headquartered in San Mateo, CA, Sagimet Biosciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Happel, the company employs approximately 16 people and listed since July 14, 2023. Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.

SGMT has shown mixed momentum, gaining 0.64% over the past week and -14.67% over the past quarter, though year-to-date performance is up 6.08%. Short-term trend indicators are bullishly aligned (SMA20 5.07%, SMA50 0.21%, SMA200 -15.13%). The stock’s 14-day RSI is 52.88 (neutral), while the ATR of 0.42 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.55% below its high and over 239.31% above its low. Average 10-day trading volume of 1.07 million shares is below the 3-month average of 1.25 million, indicating normal recent market interest.

Sagimet Biosciences Inc. trades at a P/E ratio of -8.42, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.23 suggesting the stock is closer to book value. The P/FCF stands at -8.5, also below market averages.

Sagimet Biosciences Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading above this model’s fair value.

Sagimet Biosciences Inc. generated EPS of -$1.79 over the past year. Five-year average earnings growth is -16.85%. Wall Street analysts project EPS growth of -13.95% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $49.00 to $8.00. The high target offers 357.52% upside. The low target suggests -25.3% downside. The mean target is $26.50. This offers 147.43% upside. Sagimet Biosciences Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 11, 2026, missed forecasts by 3.59%. The prior quarter beat by -15.38%. Over the last six quarters, Apple has recorded several small beats. These include -29.11% in May 08, 2025.

Sagimet Biosciences Inc. has 61.59 million shares outstanding. The public float is 55.78 million shares, elevated short interest at 19.11% of float. This equals 11.60 million shares. The short ratio is 13.08 days. Institutional investors hold 85.98% of the float. Insiders own 3.35%. NEW ENTERPRISE ASSOCIATES 13 LP holds 3.82 million shares, Happel David has 741.57 thousand shares and Rozek Elizabeth has 224.41 thousand shares. Over the past six months, insider transactions show net selling. They sold 464.63 thousand shares across 5 transactions.